Core Viewpoint - The company has announced the termination of the investment project "Annual Production of 30 million square meters of high-end optical deep-processing film" which was funded by excess raised funds [1] Group 1: Project Termination - The project has seen a total actual investment of 312.44 million yuan, including 237.56 million yuan from excess raised funds, as of January 21, 2026 [1] - The land purchase and factory construction for the project have been completed, and the remaining balance in the bank account for excess raised funds is 0.0054 million yuan [1] - The completed land and factory will serve as reserve space for the company's future projects [1] Group 2: Corporate Governance - The decision to terminate the project has been approved by the company's fourth board of directors in its ninth meeting [1] - The matter is pending approval from the company's shareholders' meeting [1]

Market Overview - The pharmaceutical and biotechnology index declined by 0.39% last week, outperforming the CSI 300 index by 0.23 percentage points but underperforming the ChiNext index by 1.50 percentage points, ranking 27th among 31 sub-industries [4] - The Hong Kong Hang Seng Healthcare Index fell by 2.75%, lagging behind the Hang Seng Index by 2.1 percentage points [4] R&D Progress - Recent clinical application advancements include BNT324 from InnoCare Pharma and HCB101 from Fuhong Hanlin [5] - QX004N from Qianxin Biopharma is in Phase I clinical trials, IBI3002 from Innovent Biologics is in Phase II, and HRS-8080 from Hansoh Pharma is in Phase III [5] Company Insights - WuXi AppTec's companies reported strong performance expectations, indicating robust growth momentum in the CXO sector [6] - WuXi AppTec is projected to achieve revenue of 45.456 billion yuan in 2025, a year-on-year increase of 15.84%, with TIDES business revenue expected to grow over 90% [6] - WuXi Biologics plans to add 209 comprehensive projects in 2025, with two-thirds being bispecific antibodies and ADC drugs, and a total of 99 projects in Phase III and commercialization [6] - WuXi AppTec's subsidiary, WuXi AppTec Co., expects revenue and adjusted net profit to grow over 45% in 2025, with a global market share increase to 24% [6] - The company aims to invest over 7 billion yuan in capacity expansion from 2026 to 2029, targeting a compound annual growth rate of 30%-35% from 2025 to 2030 [6] Investment Strategy - Future investments in the pharmaceutical sector should focus on the intrinsic clinical value logic, addressing clinical needs of patients and doctors [7] - Both domestic medical insurance policies and global expansion strategies are increasingly assigning higher premiums to clinical value [7]

Summary of Chaoyang Technology Conference Call Company Overview - **Company**: Chaoyang Technology - **Industry**: Flexible Display, Solid-State Batteries, Optical Films Key Points Industry Trends and Market Demand - Chaoyang Technology has postponed some projects due to investment pressure and market demand considerations [2][3] - Current domestic models still use CPI (Polyimide) solutions, but brands like Apple prefer UTG (Ultra-Thin Glass) combined with PET [2][3] - SKC from South Korea meets most domestic CPI demand, but no local companies have achieved stable mass production [2][12] - CPI has significant potential in commercial aerospace, particularly for solar wings, with a projected market demand of $300 million to $600 million if 10,000 satellites are launched annually, each with a solar wing area of 20 square meters [2][3] Product Developments - Chaoyang Technology has made progress in solid-state battery electrolyte composite films, achieving a thickness breakthrough to 7 micrometers and stable mass production, leading the industry [2][5] - The company is developing a lithium-ion membrane and is currently validating it with the Institute of Physics at the Chinese Academy of Sciences, expecting to launch a finished product by the Spring Festival or March [2][5] - The company plans to establish a production line with an annual capacity of 500,000 square meters in the second half of the year to meet flexible display and commercial aerospace demands [2][6] Financial Performance and Projections - The reflective film business is stable, with a global market share of approximately 55% to 60%, primarily in the liquid crystal display sector [3][9] - Expected revenue for 2026 is between 900 million to 1 billion RMB, with a gross profit of 350 million to 380 million RMB and a net profit of 150 million to 200 million RMB, maintaining stable performance [3][10] - The solid-state battery business anticipates significant production from major clients, with a capacity of 4 GW, and other client orders expected to clarify in the second half of the year [3][7] Competitive Landscape - No domestic companies have achieved stable mass production of CPI films, with only SKC having a production capacity of 800,000 to 1 million square meters [12] - Chaoyang Technology is one of the earliest entrants in the solid-state electrolyte film sector, having established relationships with major clients like Ningde, Beijing Weilan, Panasonic, and Samsung [15] - The company’s membrane thickness of 7 micrometers is significantly thinner than competitors, who typically exceed 12 micrometers, providing a competitive edge in product compatibility [15] Challenges and Risks - The dry separator business faced challenges in 2025, leading to no production due to narrow application fields and intense market competition [8] - The company plans to handle impairment of related equipment this year, which may delay impacts but has been accounted for in previous financial assessments [8][20] - The optical base film business has a small capacity of about 20,000 tons, with actual production below 10,000 tons last year, but market conditions are improving [19] Future Outlook - The solid-state battery development is seen as a gradual process, with 2026 expected to be a pivotal year for advancements in semi-solid and solid-state technologies [16][17] - The reflective film business is projected to see slight growth due to stable television demand and increasing screen sizes [18] - Overall, Chaoyang Technology is focused on enhancing product value and expanding market applications to solidify its technological leadership [6]

Group 1 - The company, Ningbo Changyang Technology Co., Ltd., has announced the release of its asset mortgage after repaying the loan principal and interest to the Export-Import Bank of China, Ningbo Branch [1][2] - The company had previously used its own land and buildings as collateral to apply for a bank credit limit of up to 300 million yuan, with a credit term of five years [1] - The asset mortgage involved the state-owned land use rights and property ownership located at No. 999 Qingfeng Road, Jiangbei District, Ningbo [1] Group 2 - The company has completed the cancellation registration of the asset mortgage rights and has retrieved the property ownership certificate [2] - The announcement was made by the company's board of directors on January 17, 2026 [2]

公司已还清中国进出口银行宁波分行贷款本金及利息，并于近日已办理完毕 了前述资产的资产抵押权注销登记，该笔资产抵押正式解除，并取回了不动产权 证书。 特此公告。 宁波长阳科技股份有限公司 关于自有资产解除抵押的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性依法承担法律责任。 一、资产抵押情况 宁波长阳科技股份有限公司（以下简称"公司"）于 2021 年 7 月 22 日召开 第二届董事会第二十次会议，审议通过了《关于公司以自有资产抵押向银行申请 综合授信额度的议案》，公司拟使用自有土地及房屋为抵押物，向中国进出口银 行宁波分行申请不超过 3 亿元银行授信额度，授信期限为 5 年，在授信期限内， 授信额度可循环使用，并授权公司董事长金亚东先生在上述授信额度范围内审核 并签署相关融资、抵押或质押担保合同文件。具体内容详见公司 2021 年 7 月 24 日在上海证券交易所网站（www.sse.com.cn）披露的《关于以自有资产抵押向银 行申请综合授信额度的公告》（公告编号：2021-042）。 上述资产抵押对应的权证为：宁波江北区庆丰路 ...

Group 1 - The company Longyang Technology stated that its reflective film and optical base film products are widely used in the liquid crystal display (LCD) field [1] - The company's products have not been applied in AI smartphones [1]

Core Viewpoint - The company Longyang Technology clarified that its reflective films and optical base films are widely used in the liquid crystal display field but have not been applied in AI smartphones [1]. Group 1 - Longyang Technology responded to an investor inquiry regarding the application of its functional films in AI smartphones [1]. - The company's products, specifically reflective films and optical base films, are primarily utilized in the liquid crystal display sector [1].

Core Viewpoint - The colored optical base film industry in China is experiencing an upward trend in market size, driven by the growth of consumer electronics and supported by government policies promoting high-end functional films. However, the growth rate has slowed down from 2022 to 2023, with a gradual recovery expected in 2024, reaching a market size of 4.267 billion yuan, a year-on-year increase of 15% [1][7]. Industry Overview - Colored optical base film is a functional material used in consumer electronics manufacturing, serving roles such as release, protection, identification, and optoelectronic tracking. It is a type of biaxially oriented polyester film (BOPET) available in various colors and specifications, crucial for the production of smartphones, tablets, and laptops [3]. Industry Policies - The government has introduced several policies to support the development of the colored optical base film industry, including the "Guidance Catalog for Industrial Structure Adjustment (2024 Edition)" which encourages high-end functional films [4]. Other policies focus on enhancing the supply capacity of key products in various sectors, including electronic chemicals and high-performance membrane materials [4]. Industry Chain - The industry chain consists of upstream components like polyester chips and additives, midstream production of colored optical base films, and downstream applications in consumer electronics, renewable energy, and photovoltaics. The demand for colored optical base films is expected to rise with the growth of the consumer electronics sector [6][7]. Current Market Status - The market size of the colored optical base film industry has been increasing, primarily due to the rapid updates in consumer electronics and the proliferation of 5G, IoT, and smart wearable devices. However, the growth rate slowed from 2022 to 2023 due to insufficient effective demand, with a recovery anticipated in 2024 [1][7]. Competitive Landscape - The market is predominantly occupied by foreign manufacturers with advanced technology. However, domestic companies like Hangzhou Heshun Technology Co., Ltd. and Jiangsu Yuxing Film Technology Co., Ltd. are emerging as strong competitors, expected to increase R&D investments to enhance market competitiveness [7]. Key Companies - Hangzhou Heshun Technology Co., Ltd. is a leading domestic player in the colored optical base film sector, with a revenue of 135 million yuan in the first half of 2025, a year-on-year increase of 6.53% [9]. Jiangsu Yuxing Film Technology Co., Ltd. is a major manufacturer of functional polyester films, reporting a revenue of 713 million yuan in the first nine months of 2025, a year-on-year decrease of 16.35% [10]. Future Development Trends - The colored optical base film industry is expected to evolve towards lightweight, flexible, and customized products. Innovations in ultra-thin technology and molecular chain structure optimization will enhance the performance of films, meeting the demands of emerging products like foldable phones and wearable devices [10]. Customization will also become a key trend, allowing companies to develop specialized products for different segments of the consumer electronics market [10].

Core Viewpoint - Zhejiang Borui Biopharmaceutical Co., Ltd. (Borui Biopharma) has submitted its IPO application to the Hong Kong Stock Exchange, standing out in the biotech industry by achieving profitability for three consecutive years amidst a challenging financing environment [3][4]. Financial Performance - In 2024, Borui Biopharma is projected to generate revenue of 1.623 billion RMB, with a net profit of 91.295 million RMB, maintaining a high gross margin of 79.5% [3][27]. - The company reported a revenue of 1.379 billion RMB and a net profit of 155 million RMB for the first three quarters of 2025, indicating a strong growth trajectory [28]. Product Development - The company's first self-developed innovative drug, Anruixi (Zebetuzumab), is expected to generate revenue of 277 million RMB in 2024, a significant increase from 10.65 million RMB in 2023, marking a growth of over 2500% [4][26]. - Borui Biopharma has a portfolio of eight commercialized products, including two innovative drugs and six mature products, with over 70% of its revenue coming from these established lines [27][28]. Investment and Financing - Borui Biopharma has completed four major financing rounds, raising over 2.04 billion RMB, with its valuation increasing from 6.6 billion RMB to 13.5 billion RMB [4][19]. - The company attracted significant investment from PAG, which acquired a 58% stake in 2019, marking one of the largest private equity investments in the biotech sector that year [16][17]. Management and Strategy - The management team has been strengthened with the appointment of Liu Min as CEO, who brings over 25 years of experience in the biopharmaceutical industry [12][14]. - The company plans to allocate 80% of its R&D investment towards innovative drugs, with over 400 million RMB spent on R&D in 2024 and 2025 [30][31]. Market Position and Competition - Borui Biopharma operates in a highly competitive market for autoimmune and oncology drugs, facing challenges from both multinational and domestic pharmaceutical companies [33][34]. - The company aims to differentiate itself through innovative drug development and has already established a strong market presence with its biosimilars [21][35].

科网股表现分化，阿里巴巴、哔哩哔哩涨逾3%，阿里健康、零跑汽车等走高；商汤跌近5%，美的集 团、快手、华虹半导体均跌超2%。 编辑 ｜ 钉钉 1月13日，香港恒生指数收涨0.9%，恒生科技指数涨0.11%。 | 名称 | 现价 | 淵跌幅 ▼ | 淵跌 | | --- | --- | --- | --- | | 瑞科生物-B | 5.720 c | 37.50% | 1.560 | | 精优药业 | 0.099 c | 11.24% | 0.010 | | 直明最科-B | 6.730 c | 9.61% | 0.590 | | 药明康德 | 120,000 c | 8.30% | 9.200 | | 三济药业-B | 86.200 c | 8.29% | 6.600 | | 百興惠图-B | 42 760 c | 8.25% | 3.260 | | 泰格医药 | 53.500 c | 8.17% | 4.040 | | 荣昌生物 | 100.100 c | 7.87% | 7.300 | | 复宏汉霖 | 68.750 c | 6.42% | 4.150 | | 药明目信-B | 2.950 c | 6.1 ...